Roche’s Tecentriq+chemo boosts survival in first-line non-small cell lung cancer

pharmafile | October 22, 2018 | News story | Research and Development, Sales and Marketing Cancer, Roche, lung cancer NSCLC, pharma, tecentriq 

Roche joined other major players like Bristol-Myers Squibb in revealing strong data on their cancer immunotherapies at the European Society for Medical Oncology (ESMO) 2018 Congress, with the Swiss pharma firm presenting new findings supporting the use of Tecentriq (atezolizumab) in combination with chemotherapy in the first-line treatment of previously untreated metastatic non-squamous non-small cell lung cancer (NSCLC).

When paired with carboplatin and Abraxane chemo, Roche’s data showed that the combo allowed patients to live “significantly longer” lives, extending median overall survival by 18.6 months compared to 13.9 months for chemotherapy alone, and also improved progression-free survival rate by 7 months as opposed to 5.5. The safety profile of the drug was also found to be consistent with previous studies, with no new safety signals reported.

“Initial treatment with this Tecentriq-based combination provided a significant survival benefit for people with non-squamous non-small cell lung cancer, the most common form of lung cancer,” remarked Dr Sandra Horning, Roche’s Chief Medical Officer and Head of Global Product Development. “Lung cancer is a complex disease and this combination could offer a new potential treatment option. We will work with global health authorities to bring this regimen to people living with this disease as soon as possible.”

Matt Fellows

Related Content


AstraZeneca shares oncology data at ASCO 2023

AstraZeneca plans to share data from its oncology pipeline at the American Society of Clinical …

AstraZeneca announces positive results from phase 3 trial for Tagrisso plus chemotherapy

AstraZeneca has announced positive results from the FLAURA2 phase 3 trial which showed that Tagrisso …

Thermo Fisher and Pfizer collaborate on NGS-based cancer tests

Scientific equipment provider Thermo Fisher and US pharmaceutical firm Pfizer have announced a collaboration to …

Latest content